Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · F-1/A

DEVONIAN HEALTH GROUP INC

DVHGFOTCEQUITYCurrent

SEC Filing

Filed Sep 2, 2026Accepted Sep 2, 2026, 4:34 PM EDTCIK 2000684Accession 0001104659-26-104757
Share

Company context

We are a biopharmaceutical company focused on developing and commercializing immunomodulatory treatments for inflammatory diseases with high unmet medical needs. Our current portfolio is comprised of treatment candidates with significant potential to address immune-mediated inflammatory diseases. Although inflammation is at the root of several known chronic health conditions1,2,3, we focus on conditions in the areas of dermatology, gastroenterology, hepatology and fibrosis. We have developed a portfolio of patented cosmetic products and are looking for a partner for its commercialization, however, we will primarily be focusing on advancing our therapeutic research and development (“R&D”) pipeline.

Current securities

Recent company filings

  1. F-1 filingJul 27, 2026

As-filed source

Primary evidence